| Identification | Back Directory | [Name]
Atractylenolide III | [CAS]
73030-71-4 | [Synonyms]
ICodonolactone
ATRACTYLENOLIDE
Atracylenolide III
ATRACTYLENOLIDE III
8-HYDROXYASTEROLIDE
Atractylenolide beta
Atractylenolide III, BR
Atractylenolide III USP/EP/BP
Atractylenolide III (ICodonolactone
Atractylenolide III000000, 98%, from Atractylodes macrocephala Koidz.
(4aS,8aR,9aS)-9a-Hydroxy-3,8a-dimethyl-5-methylidene-4,4a,6,7,8,9-hexahydrobenzo[f][1]benzoxol-2-one
(4aS)-4a,5,6,7,8,8a,9,9a-Octahydro-9aβ-hydroxy-3,8aβ-dimethyl-5-methylenenaphtho[2,3-b]furan-2(4H)-one
Naphtho[2,3-b]furan-2(4H)-one,4a,5,6,7,8,8a,9,9a-octahydro-9a-hydroxy-3,8a-dimethyl-5-methylene-,(4aS,8aR,9aS)- | [Molecular Formula]
C15H20O3 | [MDL Number]
MFCD00238543 | [MOL File]
73030-71-4.mol | [Molecular Weight]
248.32 |
| Chemical Properties | Back Directory | [Melting point ]
166-169 °C(Solv: chloroform (67-66-3)) | [Boiling point ]
424.6±45.0 °C(Predicted) | [density ]
1.18±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
methanol: soluble1mg/mL, clear, colorless | [form ]
powder or crystals | [pka]
10.73±0.60(Predicted) | [color ]
white to off-white | [biological source]
Atractylodes macrocephala Koidz. | [InChIKey]
FBMORZZOJSDNRQ-GLQYFDAESA-N |
| Hazard Information | Back Directory | [Uses]
Atractylenolide III enhances energy metabolism by increasing the SIRT-1 and PGC1α expression. | [Definition]
ChEBI: Atractylenolide III is a naphthofuran. It has a role as a metabolite. | [Biological Activity]
Atractylenolide III possesses anti-inflammatory and anticancer properties. | [in vivo]
Atractylenolide III (5 and 10 mg/kg, p.o.) shows gastroprotective effects and reduces 70% ethanol-induced gastric ulcer in rats[2].
Atractylenolide III (30 mg/kg, oral gavage for 14 days or 28 days) reduces depressive- and anxiogenic-like behaviors in rat depression models in Lipopolysaccharide (LPS) (HY-D1056) and chronic unpredictable mild stress (CUMS) induced rat depression model[5].
| Animal Model: | 70% ethanol-induced gastric ulcers in rats[2] | | Dosage: | 5 and 10 mg/kg | | Administration: | p.o. | | Result: | Inhibited gastric ulcer formation and the necrotic erosion of gastric mucosa.
Downregulated the MMP-2/9 expression by activating the TIMP-2 and TIMP-1 expressions. |
|
|
|